CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)

April 21, 2023

https://www.globenewswire.com/news-release/2023/04/21/2651878/37067/en/CymaBay-Therapeutics-Announces-Publication-of-Results-From-the-ENHANCE-Phase-3-Study-of-Seladelpar-in-Patients-with-Primary-Biliary-Cholangitis-PBC.html

NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the ENHANCE phase 3 global study evaluating seladelpar for primary biliary cholangitis (PBC) have been published in Hepatology:

Read more at globenewswire.com

Related news for (CBAY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.